Georg Schroeckenfuchs – President, Middle East & Head, MEA Cluster, Novartis

28.02.2020
Georg Schroeckenfuchs, Novartis’ president for the Middle East and head of MEA cluster, is a 32-year veteran of the pharmaceutical industry and describes the company’s footprint within the MEA region, provides insights into its strategy of segmenting their markets into three categories. Furthermore, he discusses the company’s strategic priorities when entering the region and the innovative and attractive ecosystem the UAE has to offer.  
The MENA region is key for Novartis because it currently produces USD 1.4 billion in sales for the company
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
UAE, Novartis, MEA, MENA, Market Access, Innovation

Related Interviews

Abbas Virji & Shalina Clifford – Co-CEOs, Shalina Healthcare, UAE

Sub-Saharan Africa might not be considered among the top destinations for the global pharmaceutical industry, but Shalina Healthcare considers it home and has established itself as the leading pharma company…

Ronald Boueri – General Manager, Zimmer Biomet Middle East

Ronald Boueri of Zimmer Biomet Middle East discusses the challenges of establishing the business, the importance of providing the latest innovation and assistance to medical professionals in the MENA (Middle…

Tarek El Rahbani – Managing Director MENA, Boston Scientific

Working non-stop to catch up with its footprint in other regions, Boston Scientific is investing heavily in the MENA markets. Tarek El Rahbani, managing director for the region, shares the…

Related Articles

MEA / 3 Regional Pharma Managers on their Middle East Go-To-Market Strategies

The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma…

MEA / The Pharma Commercialisation Model of the Future

Amgen MEA’s Mohamed Nasser* examines the current pharma commercialisation model, posits how the entire healthcare ecosystem’s rapid and effective response to COVID-19 could be replicable in other disease areas, and…

MENA / Egypt Opens 'Pharma City'; Koçak’s COVID Vaccine Enters Phase I; Abu Dhabi Strengthens Hub Status

The latest Middle East and North Africa (MENA) pharma, including Egypt’s opening of the largest “pharmaceutical city” in the Middle East and Abu Dhabi’s quest to become a pharma hub…

Latest Report

Saudi Arabia Pharma Report 2022

Related Content

UAE
Novartis
MEA
MENA
Market Access
Innovation